One fund mixes U.S. and international property. The other focuses only on real estate outside the United States for much less. Here is how to choose.
XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.
Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
The cost gap is wide, but the bigger difference lies in which banks each fund holds and how far each has fallen during market stress.
The U.S.-only fund carries half the expense ratio and posted stronger one-year returns, but its global peer spreads risk across international and emerging markets.
The fund bought $84.3 million of stock, lifting 21 positions and trimming none, with Meta and both Alphabet share classes the largest additions.
KBE carries a lower fee and higher yield, yet FTXO's concentrated 50-stock portfolio tells a different story about risk and reward.
The State Street SPDR S&P Kensho New Economies Composite ETF has lagged the S&P 500, but this tech-focused fund is built for long-term disruptive growth.
USB, STT and KEY could benefit from higher interest rates, improving loan demand and industry tailwinds, while strategic expansion supports earnings growth.
The fund added $196.0 million across 501 positions on Tuesday, with Apple, Nvidia and Microsoft leading the buys.
Both funds charge just 0.08%, but their holdings counts differ sharply, and long-term returns reveal a narrow gap.
One fund lends to companies and pays more. The other lends to the U.S. government and offers more safety. Here is how to choose.
One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
This is the newest page. Registered accounts read further back.